Commonwealth Equity Services, LLC Cybin Inc. Transaction History

Commonwealth Equity Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$0.26 - $0.46 $244 - $432	-940 Reduced 2.11%	43,658 $12,000
Q1 2024 Apr 29, 2024	BUY	$0.3 - $0.46 $2,627 - $4,029	8,759 Added 24.44%	44,598 $18,000
Q4 2023 Feb 06, 2024	SELL	$0.38 - $0.65 $2,081 - $3,560	-5,478 Reduced 13.26%	35,839 $15,000
Q2 2023 Aug 10, 2023	BUY	$0.23 - $0.39 $1,154 - $1,957	5,020 Added 13.83%	41,317 $16,000
Q1 2023 May 11, 2023	BUY	$0.3 - $0.56 $3,421 - $6,386	11,405 Added 45.82%	36,297 $14,000
Q4 2022 Feb 07, 2023	SELL	$0.26 - $0.64 $475 - $1,171	-1,830 Reduced 6.85%	24,892 $7,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.11 $2,880 - $6,660	6,000 Added 28.95%	26,722 $12,000
Q1 2022 May 04, 2022	BUY	$0.74 - $1.22 $5,823 - $9,601	7,870 Added 61.24%	20,722 $16,000
Q4 2021 Jan 31, 2022	BUY	$1.13 - $2.31 $736 - $1,506	652 Added 5.34%	12,852 $15,000
Q3 2021 Oct 29, 2021	BUY	$1.83 - $3.18 $22,326 - $38,796	12,200 New	12,200 $26,000

185K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $2.07B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.